Suchergebnisse - "Wingerchuk, Dean M"

PubPharm (270)

11

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder

enthalten in: Frontiers in neurology | 2023

von Berthele, A. | Levy, M. | Wingerchuk, D. | +6

12

Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder

enthalten in: Journal of managed care & specialty pharmacy | 2022

von Wingerchuk, D. | Weinshenker, B. | McCormick, D. | +3

13

A Response to : Letter to the Editor Regarding "Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder"

enthalten in: Neurology and therapy | 2022

von Wingerchuk, D. | Zhang, I. | Kielhorn, A. | +7

14

In Patients With Melanoma Brain Metastases, Is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic

enthalten in: The neurologist | 2022

von Gritsch, D. | Mrugala, M. | Marks, L. | +2

15

Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD

enthalten in: Neurology | 2022

von Shah, S. | Morris, P. | Buciuc, M. | +9

CommentIn: Neurology. 2023 Feb 7;100(6):310. - PMID 36746640

16

Neuromyelitis Optica Spectrum Disorder

enthalten in: The New England journal of medicine | 2022

von Wingerchuk, D. | Lucchinetti, C.

17

A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”

enthalten in: Neurology and Therapy | 2022

von Wingerchuk, D. | Zhang, I. | Kielhorn, A. | +7

18

A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”

enthalten in: Neurology and Therapy | 2022

von Wingerchuk, D. | Zhang, I. | Kielhorn, A. | +7

19

Eculizumab monotherapy for NMOSD : Data from PREVENT and its open-label extension

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2022

von Pittock, S. | Fujihara, K. | Palace, J. | +11

20

Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder

enthalten in: Neurology and therapy | 2022

von Wingerchuk, D. | Zhang, I. | Kielhorn, A. | +7